CRYOPORT, INC. Finance Lease, Right-of-Use Asset, before Accumulated Amortization
CRYOPORT, INC. (CYRX) had Finance Lease, Right-of-Use Asset, before Accumulated Amortization of $2.00 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Leases › Assets and Liabilities, Lessee › Finance Lease, Right-of-Use Asset, after Accumulated Amortization
us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization · last filed 2026-03-05
- 2025-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $2.00M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $1.50M; Finance Lease, Right-of-Use Asset, before Accumulated Amortization as first filed $1.70M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $1.20M.
| Period end | Finance Lease, Right-of-Use Asset, before Accumulated Amortization | Finance Lease, Right-of-Use Asset, before Accumulated Amortization as first filed |
|---|---|---|
| 2025-12-31 | $2.00M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $1.50M 10-K · filed 2026-03-05 | $1.70M 10-K · filed 2025-03-07 |
| 2023-12-31 | $1.20M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |